INmune Bio, Inc. (INMB)

US — Healthcare Sector
Peers: TFFP  ANEB  ABCM  ANTX  CUE  ANIX  INAB  PYPD  AVTE  ELYM  DBTX  AVXL  SAVA  BIVI  CGTX  TCRX  DRMA 

Automate Your Wheel Strategy on INMB

With Tiblio's Option Bot, you can configure your own wheel strategy including INMB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol INMB
  • Rev/Share 0.0022
  • Book/Share 1.319
  • PB 5.451
  • Debt/Equity 0.0117
  • CurrentRatio 2.6441
  • ROIC -1.0487

 

  • MktCap 166882776.0
  • FreeCF/Share -1.454
  • PFCF -5.102
  • PE -3.9648
  • Debt/Assets 0.0092
  • DivYield 0
  • ROE -1.1866

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation INMB Rodman & Renshaw -- Buy -- $23 Jan. 28, 2025
Initiation INMB Alliance Global Partners -- Buy -- $20 Oct. 21, 2024
Initiation INMB Raymond James -- Outperform -- $18 Sept. 27, 2024
Initiation INMB Scotiabank -- Sector Outperform -- $22 Aug. 22, 2024

News

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
INMB
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort.

Read More
image for news INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
INMB
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients.

Read More
image for news INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

About INmune Bio, Inc. (INMB)

  • IPO Date 2019-02-04
  • Website https://www.inmunebio.com
  • Industry Biotechnology
  • CEO Dr. Raymond Joseph Tesi M.D.
  • Employees 13

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.